Biovotec AS secured the establishment of a guarantee consortium of targeted NOK 15 Million. The guarantee consortium builds on the company goals, and enables to move forward into human clinical studies.
After only 3 weeks of actively establishing the consortium at the end of July, the targeted amount of the establishment was completed.
“Having done this placement in only 3 weeks with a newly formed company is outstanding, especially when you consider that more than half the guaranteers are new to the Biovotec family.” - Ralf Schmidt, CEO at Biovotec
The signing of the guarantee consortium was conducted at a pre money valuation of NOK 150 million.
I'm busy working on my blog posts. Watch this space!